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1. Nature sources of paclitaxel
The National Cancer Institute analyzed the content of 
an extract from a bark of Pacific yew (Taxus brevifolia), 
first isolated from a plant material in 1963 [1]. The Pa-
cific yew is a rare, low-growing evergreen plant, locating 
in the old forests of the northwestern Pacific. Preclini-
cal studies of the extract showed that it had a cytostatic 
activity on many types of tumors [2]. In 1971, paclitaxel 
was identified as an active constituent of this extract. 
Development of paclitaxel for medicinal use proceeded 
slowly despite its antitumor activity because collecting 
sufficient amount required much time and plant mate-
rial (for about 1 kg yield, it is necessary to isolate the 
extract from 3,000 of Pacific yew trees). Interest in this 
substance was aroused in 1979, when its mechanism 
of action as an antitumor drug was identified [3-5]. Pa-
clitaxel is also contained in Taxus yannanensis, and has 
been obtained from Taxus baccata by semi-synthesis.
 Stierle et al. [6] indentified the fungus of Taxomyces 
andreanae that produces paclitaxel. Although the yield 
of paclitaxel was tiny (24–50 ng/dm3), this discovery was 
of major interest to scientists [7]. Several procedures 
have been suggested for isolation from the endophytic 
fungus [8-10], showing that microorganism of Taxus 
species can produce paclitaxel. Therefore, the process 
of fermentation using a paclitaxel-produced microorgan-
ism represents an alterative procedure for paclitaxel 
production. The major problems involved in fungus fer-
mentation are the very small yield of paclitaxel and its 
instability: the yields ranged from 24 ng to 70 μg per 
liter of the investigated fungus [6,8]. The microspore of 
Pestalotiopsis CP-4 [9] produced paclitaxel from 50 to 
1487 ng/dm3. The goal of the present research is dis-
covering the optimal fermentation conditions for Taxus 
cell cultures.
 Although the amount of the produced paclitaxel from 
fungus was lower than those that were obtained from 
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yews, the shorter production time and high rate of fun-
gus growth have had an important role in further studies. 
After almost two years of research, scientists have iso-
lated several endophytic funguses from Taxus chinensis 
var. mairei and Taxus yunnanensis. Species of Ozonium 
BT2 can also produce paclitaxel and taxane baccatin III 
(intermediates in the production of paclitaxel).
 Production of paclitaxel by a microbiological pathway 
is also possible using a pure culture of Actinomycetes 
[11]. Microorganisms from the Actinomycetes group 
usually belong to the suprageneric group of Streptomy-
cetes, Actinoplanetes, Maduromycetes, Thermomonos-
poras or Nocardioforms, but more often to the Strep-
tomyces, Actinoplanes, Nocardiopsis, Micromonospora, 
Actinomadura or Kitasatosporia genus, and mostly to 
the Kitasatosporia genus. Among them, the most signifi-
cant is Kitasatosporia sp. CECT 4991.
2. General characteristics of paclitaxel 
The IUPAC name for paclitaxel is (2α,4α,5β,7β,10β,13α)-
4,10-bis(acetyloxy)-13-{[(2R,3S)-3-(benzoylamino)-
2-hydroxy-3-phenylpropanoyl]oxy}-1,7-dihydroxy-9-
oxo-5,20-epoxytax-11-en-2-yl benzoate. Its structural 
formula is shown at Figure 1, and Table 1 lists its char-
acteristics. 
 Paclitaxel is soluble in dimethyl sulfoxide (DMSO) 
(50 mg/cm3) [6]. A 0.01 mol/dm3 solution of paclitaxel 
in DMSO has been stored as aliquots until use and fur-
ther diluted to 10-10 mol/dm3 with medium [12]. Paclitaxel 
is also soluble in methanol (50 mg/cm3). It undergoes 
hydrolysis and transesterification to ~30% of the peak 
signal at 227 nm by a high performance liquid chro-
matography method (HPLC) after two weeks at room 
temperature. Paclitaxel is rapidly destroyed in weakly 
alkaline, methanolic solutions and in strongly acidic 
methanolic solutions (1:1 of methanol : concentrated 
HCl). A sample with 0.1% acetic acid added to methanol 
showed no signs of degradation for seven days at room 
temperature or three months at 4°C (presumably due to 
the ability of the acetic acid to neutralize traces of alkali 
in the methanol) [13]. Paclitaxel is also soluble in etha-
nol and acetonitrile [14].
 Paclitaxel has low solubility in water and is rapidly 
destroyed in weakly alkaline aqueous solutions [13]. 
The lowest amount of degradation in aqueous paclitaxel 
solutions occurs in pH 3 to 5. Paclitaxel solutions at 0.1 
and 1 mg/cm3 in 5% dextrose injection or 0.9% sodium 
chloride injection remained active for at least three days 
at 4, 22, or 32°C [15]. 
3. Paclitaxel procedures of isolation 
from natural sources
The first step involves washing raw plant material using 
deionized water [16]. The temperature of water is in the 
range of 20 to 25°C, and duration of the process is 3 h. 
Then, the water is removed along with all water soluble 
impurities. The second step is extraction with an organic 
solvent. The adequate solvents for this extraction are 
alcohols (methanol), ketones (acetone) and their mix-
tures. In cases where a mixture is used, the volume ratio 
in the mixture is about 1:1. The obtained extract is fil-
tered to remove deposits, and then transferred to a dou-
ble walled tank, where the water temperature is in the 
range of 65–70°C. The organic solvent is then removed 
by distillation. The remaining solution is drained into an-
other tank. Because there is residual water, that solution 





DMSO, methanol, ethanol. Unstable in 
Methanol.
Consistency White crystalline solid.
λmax 227, 273 nm
Melting point (decomposition) 200-220 °C
Solubility
Clear colorless solution at 10 mg·cm-3 of 
methanol.




Storage -20 °C. Protect from light.
Warnings
Warning! May cause birth defects. Irritates 




Table 1. General characteristics of paclitaxel
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of biomass from the solution obtained in the previous 
step. The extract is diluted in methanol and water and 
then salted out to precipitate the biomass. Sodium chlo-
ride is quickly added to the extract under heavy stirring. 
The formed biomass is separated from the solution by 
filtration or by centrifugation. The separated biomass, 
which is wet, can be dried by ventilation or lyophilization. 
The fourth step removes the resin and natural pigments 
by treating the dried biomass with mixture of acetone 
and hexane. An even better procedure is to put the dried 
biomass back into solution by first adding the mixture of 
acetone and hexane and adding 1.5 additional volumes 
of pure hexane. The final ratio of acetone and hexane 
is 1:4. Then, pure water is added to the obtained solu-
tion to form a paclitaxel-enriched oily phase, which is 
then transferred into decanting desk. The oily phase 
at the bottom of the flask contains paclitaxel and oth-
er taxanes. The fifth and final step is chromatographic 
purification of a solution of the paclitaxel-enriched oily 
phase and crystallizing the purified solution obtained by 
chromatography at least once. In this procedure, the pa-
clitaxel-enriched oily phase is first mixed with silica gel 
and dried under ventilation. The silica gel coated with 
the oily phase is loaded onto a chromatographic column 
containing the same type of gel. The purification is con-
ducted using the mixture comprising 35% of acetone 
and about 65% hexane. The fractions containing pacli-
taxel obtained by chromatography in the preceding step 
are evaporated to dryness and put back in an acetone 
solution. Then, the paclitaxel is crystallized by adding 
from 3 to 4 volumes of hexane to the acetone solution.
 One published procedures uses acetone as an ap-
propriate solvent for isolation of paclitaxel from plant 
material [17]. Acetone/water precipitation gives a very 
pure paclitaxel, which is useful for industrial scale isola-
tion and normal-phase silica chromatography.
 Accelerated solvent extraction (ASE) has been in-
vestigated under different conditions for isolation of pa-
clitaxel and related analogue compounds from the bark 
of Taxus cuspidata (Japanese yew) [18]. This method 
uses more pressure in the cells to keep the solvent 
warm during the extraction. In this procedure, the time 
of extraction is shorter and the amount of desired prod-
uct is higher. The conditions under which the obtained 
yield of paclitaxel is the highest are the following: sol-
vent, MeOH : H2O (90:10 v/v); temperature, 150°C; and 
pressure, 10.13 MPa (the yield after drying the sample 
was 0.128% m/m). ASE does not require a chlorinated 
solvent. It reduces the use of solvent, because of higher 
dissolving power. The obtained amount of paclitaxel and 
related compounds during ASE is higher even when wa-
ter is used as the solvent as compared the yield from 
other methods.
 A simple and efficient procedure of extraction was 
developed and optimized using enzymes to obtain of 
paclitaxel and the related compounds 7-xyl-10-deacetyl-
paclitaxel, 10-deacetylpaclitaxel, cephalomannine and 
7-epi-10-deaceylpaclitaxel from needles of Taxus chi-
nensis [19]. The optimal procedure of extraction begins 
with treatment with a cellulose solution of 1 mg·dm-3, a 
liquid to solid ratio 1:10 (cm3/g), and incubation at pH 
4 and 40°C for 24 h. Under these optimal conditions, 
the yields of paclitaxel, 7-xyl-10-deacetylpaclitaxel, 
10-deacetylpaclitaxel, cephalomannine and 7-epi-
10-deaceylpaclitaxel were 1.78, 1.26, 2.46, 3.01 and 
2.25-times higher than in beta-glucosidase, respec-
tively. Additionally, the influence of enzymes on the 
structural changes of the plant cells was observed by 
scanning electron microscopy (SEM). The extraction us-
ing enzymes was improved for ecologic and economic 
reasons for large-scale natural product extraction.
4. Semi-synthesis of paclitaxel
An initial substance for semi-synthesis of paclitaxel is 
10-deacetylbaccatin-III (10-DAB), which can be isolated 
from needles and wattles of the European yew (Taxus 
baccata) [20]. There are two procedures for synthesis, 
both of which start with 7-O-TES-baccatin-III obtained 
by selective silylation and acetylation of 10-DAB [21]. In 
the first procedure developed and published in the pat-
ent literature by Holton [22], lithium ions are reacted with 
β-lactam to introduce a desirable amino acid chain at 
the 13-position. Bristol-Myers Squibb Co [23], and also 
[24] presented the second procedure for synthesis in the 
patent literature. 7-O-TES-baccatin-III was reacted with 
oxazolinecarboxylic acid ((4S-trans)-4,5-dihydro-2,4-di-
phenil-5-oxazolecarboxylic acid) using dicyclohexylcar-
bodiimide (DCC) or a similar dehydrating agent. A third 
synthetic procedure is based on coupling 7-O-Troc-
baccatin-III with the protected β-phenylisoserine using 
DCC [25].
5. Total synthesis of paclitaxel
The structural elements of paclitaxel (Figure 1), in ad-
dition to the main A, B and C rings, include an oxetan 
ring (D-ring), an N-benzoyphenylisoserine side chain 
appended to C-13 of the A ring and the benzoate group 
at C-2 of the B ring [7]. Two groups of scientists [26,27] 
have published procedures of total synthesis of pacli-
taxel with low yields at 2.7% and 0.07%, respectively. 
Nicolaou’s group started first with construction of the A 
and C rings separately and then coupling the two mol-
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ecules using a Shapiro and McMurry coupling to form 
the B ring. Further reactions were carried out to produce 
the final product of paclitaxel. Holton et al. started with 
(-)-borneol, which they converted to an unsaturated ke-
tone through 13 synthetic steps. Two years later, Dan-
ishefsky et al. published a third procedure, which had 
fewer steps than Holton’s and Nicolaou’s procedures 
[28]. The method used the Wieland-Miescher-ovim ke-
tone as a starting material, which was then converted 
to a complex enol triflate containing an olefin on the C 
ring that allowed for the development of paclitaxel via 
an intramolecular Heck reaction. Morihira and cowork-
ers have published yet another procedure for pacli-
taxel synthesis [29]. These procedures represent great 
achievements in the scientific community, but still can-
not be used for industrial production, because in several 
synthetic steps the yields of intermediates are very low. 
Therefore, these total synthesis methods of paclitaxel 
production are too expensive and too complex.
6. Complexes of paclitaxel
Pharmaceutical substances are usually insoluble in 
water; therefore, increased solubility is important for a 
drug to be administered intravenously. Different types 
of carriers that increase solubility, such as cyclodextrins 
[30 -32] oligosaccharides (dextrane, pullulan) [33,34], 
liposomes, and polymers, have been tested. These 
substances provide better absorption of the active sub-
stance during a treatment of a disorder. Coupling a bio-
active compound to a biocompatible polymer offers, in 
general, many advantages, such as better drug solu-
bilization, better stabilization, specific localization, and 
controlled release.
 Cyclodextrins (CyD) are complexing agents that can 
increase the solubility and stability of poorly soluble ac-
tive substances [35]. Studies have been done on the 
different types of β- and γ- CyDs. (Hydroxypropyl)-(HP 
β-CyD), (hydroxyethyl)-(HE β-CyD) and dimethyl-(DM 
β-CyD) β-CyD belong to this group; they increase the 
solubility of paclitaxel by a factor of 2,000 without chang-
ing the cytostatic activity of paclitaxel in vitro. The amount 
of dissolved active substance increased with increasing 
cyclodextrin concentration. In some cases, the precipita-
tion of cyclodextrins in solution was observed. Thermal 
and spectroscopic analyses (fluorescence, IR, NMR and 
circular dichroism) confirmed the formation of complexes, 
which were more stable in the solid form than in the solu-
tion. This can be explaine the occurrence of precipitate 
in the solution. DM β-CyD solutions of ≤ 3.7 mol% (mol 
paclitaxel/mol cyclodextrin) showed no precipitation upon 
dilution, nor did HP β-CyD solutions of ≤ 0.14 mol%.
 The solubility and bioactivity of inclusion complexes 
of paclitaxel using 11 different cyclodextrins, (α-CyD, 
β-CyD, γ-CyD, mono-6-O-maltosyl α-CyD (G2-α-CyD), 
mono-6-O-maltosyl β-CyD (G2-β-CyD), mono-6-O-
maltosyl γ-CyD (G2-γ-CyD), heptakis-(2,6-di-O-methyl) 
α-CyD (DM-α-CyD), heptakis-(2,6-di-O-methyl) β-CyD 
(DM-β-CyD), heptakis-(2,3,6-tri-O-methyl) β-CyD (TM-
β-CyD), hydroxyethyl β-CyD (HE-β-CyD), hydroxypro-
pyl β-CyD (HP-β-CyD)), was studied by Hamada and 
coworkers [36]. From this group of cyclodextrins, 2,6-di-
methyl β-CyD was shown to be the most efficient, with 
the solubility of paclitaxel at 2.3 mmol/dm3 in a cyclodex-
trin solution of 0.1 mmol/dm3. This inclusion complex of 
paclitaxel has 1.23 times higher polymerization activity 
than paclitaxel in tubulin.
 Today, the formulation on the basis of the inclusion 
complexes of cyclodextrin and paclitaxel is used [35], 
most commonly with a paclitaxel to cyclodextrin ratio of 
1:10 to 1:150. Different types of cyclodextrins, such as 
hydroxypropyl-sulphobutyl-7-β-CyD, sulphobutylether-
7-β-CyD, acetyl-γ-CyD, hydroxypropyl-β-CyD, 
hydroxypropyl-γ-CyD, bis(β-CyD), γ-CyD, succinyl-
methyl-β-CyD, anionic-β-CyD, as well as their mixtures, 
can be used for making these formulations. The stability 
constant of these inclusion complexes lie in the range 
Ka = 5.396 – 1.412 dm3/mol. Preparing the formulations 
is done in the following manner: (a) the solution of cy-
clodextrin is added dropwise to the ethanol solution of 
paclitaxel. (b) After the paclitaxel dissolves, the obtained 
mixture is filtered through a microporous membrane 
(0.2–0.4 μm) (c) Then, ethanol is removed at low pres-
sure, giving a liquid inclusion that contains less than 2% 
ethanol. The residual water is also removed in the same 
way. Paclitaxel (20 mg/cm3) remains more active in cy-
clodextrin solutions (10%–20%) than in buffer solutions 
of comparable pH [37]: There was less than 1% decom-
position of paclitaxel in the cyclodextrin solutions stored 
for one month at 37°C.
 The incorporation of paclitaxel into hydrotropic poly-
meric micelles, with a shell of poly(ethylene glycol) 
(PEG), and a core of poly(2-(4-vinylbenzyloxy)-N,N-di-
ethylnicotinamide) (P(VBODENA), has been described 
[38]. This procedure improved the solubility and stability 
of paclitaxel. To study the stability, a control was used in 
which paclitaxel was incorporated in polymeric micelles 
of poly(ethylene glycol)-b-P(D,L-lactide) (PEG-b-PLA). 
The maximal amount of paclitaxel incorporated in the 
micelles of PEG-b-P(VBODENA) was higher than 37.4 
mass%, compared with the 27.6 mass% in the micelles 
of PEG-b-PLA. Above 30 mass% of paclitaxel was locat-
ed inside polymeric micelles in a molecularly dispersed 
amorphous state, as confirmed by thermal analysis. Hy-
drotropic polymer micelles can remain stable for a few 
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weeks, while micelles of PEG-b-PLA precipitate after a 
few days. Hydrotropic polymer micelles are also more 
efficient than PEG-PLA micelle formulations in inhibiting 
the proliferation of human cancer cells. Paclitaxel in the 
form of hydrotropic polymer micelles has been adminis-
tered to rats orally (3.8 mg/kg), intravenously (2.5 mg/
kg), or through the portal vein (2.5 mg/kg). The results 
of research showed that the polymer micelles with a hy-
drotropic structure were the better carriers, because of 
their high solubility and long-term stability.
 Paclitaxel-loaded poly(ε-caprolactone)(PCL)/pluron-
ic F68 (F68) nanoparticles were spherical with a porous 
surface [39]. F68 was incorporated in the matrix of PCL. 
These substances are usually used as an agent for for-
mation of pores. Paclitaxel-loaded PCL/F68 nanopar-
ticles were shown to be more efficient than conventional 
injections of paclitaxel. Therefore, paclitaxel-loaded 
PCL/F68 nanoparticles can effectively prevent tumor 
cell growth. These data suggest an eventual possible 
use of this preparation for treatment of breast cancer.
 Nanoparticles were formulated with pluronic F-68 
and liquid PEG (Mr 400) using a rapid, simple, and con-
tinuous procedure without presence of solvents [40]. 
Paclitaxel was contained in these nanoparticles (Figure 
2). The liquid PEG was used as a solubilizer of pacli-
taxel. A liquid polymer mixture was formulated from the 
emulsion of PEG, paclitaxel and pluronic F-68. On a 
nanometer scale, PEG/paclitaxel was incorporated in 
pluronic F-68 by cooling at 0°C until the appearance of 
pluronic nanoparticles. The morphology and size of the 
pluronic nanoparticles formed can be observed using 
FE-SEM and TEM. These studies were done on tumor 
mice to investigate a use of pluronic nanoparticles as 
a system for controlled release of active substance in 
tumor treatment. Also, the time-dependent excretion 
profile, in vivo biodistribution, and circulation time was 
evaluated. The paclitaxel-loaded was rapidly released in 
the first 7 h. Up to 48 h, the paclitaxel release remained 
constant. The paclitaxel-loaded pluronic nanoparticles 
were more efficient compared with paclitaxel formulated 
in Cremophor EL.
 Phospholipids in combination with aqueous solvent 
or hydrophilic polymers, as PEG, were used as a matrix 
for incorporation of paclitaxel molecules [41]. The par-
ticles formed had an average size of 1000 nm. Conju-
gates on the basis of linear biodegradable copolymers 
of N-(2-hydroxypropyl) methacroylamide (HPMA) and 
units of methacryloylated hydrazones of amino acids 
and oligopeptides with paclitaxel have been described 
in the literature [42]. The research was also moved in 
the direction of obtaining a polymer analog. Hyaluronic–
paclitaxel hydrosoluble bioconjugates appear promis-
ing as cancer therapy. Their cytotoxicity against various 
cancer cell lines is, in fact, comparable to that of free 
paclitaxel, and the systemic toxicity is reduced owing to 
selective targeting of cancer cells [43].
 Application of paclitaxel in the form of intravenous 
infusion required lecithin as a carrier [44]. A paclitaxel 
concentration of 1 mg/cm3 was achieved in 24 h by 
making micelles. Aqueous dispersions of egg or soya 
lecithin (water-lecithin dispersion, WLD), and mixed mi-
cellar (MM) solutions of lecithin from egg and sodium 
deoxycholate were investigated. Also, a new formulation 
with lecithin, co-surfactants and co-solvents poloxamer, 
polysorbate, Span, benzalkonium chloride, and mac-
rogol were developed. The amorphous paclitaxel was 
prepared by lyophilization. Unlike crystalline paclitaxel, 
the drug in an amorphous form is easily soluble in a 1% 
to 5% (w/w) WLD or MM. The highest solubility (up to 
5.70 mg/cm3) was achieved in 5% WLD. Dissolved pa-
clitaxel precipitated in all investigated formulations after 
24 h. Otherwise, paclitaxel concentration of 1 mg·cm-3 
after 24 h in 5% egg WLD, 1% to 5% soya WLD, and 
in 5% MM (lecithin : deoxycholate ratio 1 : 1 w/w). After 
24 h, precipitation of paclitaxel was not noted for differ-
ent batches of 5% WLD. That formulation was adequate 
for further in vivo studies. The solubility of paclitaxel in 
lecithin is not increased by addition of surfactants and 
co-lyophilization.
7. Methods for isolation and purifica-
tion of paclitaxel from plant materials
Paclitaxel was isolated from a crude plant extract by 
normal phase chromatography [45]. Polyamide was 
used as the stationary phase, with a mixture of dialkyl 
ketone and weakly polar solvent as the mobile phase. 
Acetone and methyl isobutyl ketone are dialkyl ketones, 
while (C5-C8) aliphatic hydrocarbons, (C6-C8) aromatic 
hydrogencarbons, (C1-C4) dialkyl ether to weakly polar 
co-solvents. The otained chromatogram at exposed 
conditions is shown as Figure 3.Figure 2. Procedure for making nanoarticles of paclitaxel with 
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An improved method for separation of paclitaxel and its 
analogs from Taxus species includes treating the extract 
by reverse-phase liquid chromatography on the adsor-
bent [46]. First, paclitaxel and its analogs are adsorbed 
on the adsorbent and then eluted. The compounds, 
which are isolated in pure form, are paclitaxel, paclitaxel-
7-xyloside, 10-deacetylpaclitaxel, 10-deacetylpaclitaxel-
7-xyloside, cephalomannine, cephalomannine-7-xylo-
side, 10-deacetylcephalomannine-7-xyloside, baccatin 
III, 10-deacetylbaccatin III, baccatin VI, brevitaxane A 
and taxiflorine. The simple and efficient procedure for 
isolation of paclitaxel from the bark of Taxus brevifolia is 
described in literature [47]; this method uses a reverse 
phase C18 column.
8. Paclitaxel mechanism of action
Paclitaxel is a complex diterpene with antitumor activ-
ity against ovarian, breast, lung, and prostate cancer 
[14,48], and acts as a promoter of tubulin polymeriza-
tion and stabilizes microtubules to depolymerization by 
different agents, both in vitro and in vivo [49,50]. Pa-
clitaxel alters the normal equilibrium between tubulin 
dimmers and microtubules, and, therefore, disrupts cell 
division [51]. The paclitaxel-stabilized microtubules are 
resistant to depolymerization upon exposure to calcium 
ions and cold temperatures, and do not require the pres-
ence of guanosine triphosphate (GTP) [14,50]. Unlike 
other spindle poisons, which prevent polymerization of 
the monomer, paclitaxel has a binding site on the micro-
tubule [14].
 The proposed mechanism of action, metabolism, 
relationship between structure and activity, such as 
pharmacokinetics of paclitaxel, have been explained 
in the literature [14,49,52-58]. Analogs of paclitaxel 
having good biological activity have been synthesized 
[14,48,51,52,57,59,60]. 
 Paclitaxel in concentrations as low as 0.05 μmol/
dm3 promoted microtubule assembly in vitro, even in 
the absence of GTP or microtubule-associated pro-
teins (MAPs) [61]. Studies of HeLa cells and fibroblasts 
treated with paclitaxel (0.25 or 10 µmol/dm3) show that 
paclitaxel blocks cells in the G2 and M phase of the cell 
cycle [62]. More than 90% of the cells treated with 10 
µmo1/dm3 taxol for 22 h at 37°C displayed bundles of 
microtubules that appeared to radiate from a common 
site (or sites), in addition to their cytoplasmic microtu-
bules. Untreated cells that were kept in the cold (4°C) for 
16 h lost their microtubules, whereas cells that were pre-
treated with taxol for 22 h at 37°C continued to display 
their microtubules and bundles of microtubules in the 
cold. HeLa (human) cells, strain S3, were grown in sus-
pension culture in Joklik’s modified Eagle’s minimal es-
sential medium supplemented with 5% fetal calf serum 
and 1% glutamine. A primary cell line of male BALB/c 
mouse fibroblasts (provided by Susie Chen) and Swiss 
3T3 mouse fibroblasts were grown as monolayers in 
Dulbecco’s modified Eagle’s medium supplemented 
with 10% fetal calf serum. Fibroblast cells used in the 
experiments were no older than 20 passages.
 In nonmalignant cells, paclitaxel inhibits specific 
functions such as chemotaxis, migration, and cell 
spreading. It inhibits the slow transportation of tubulin, 
actin, and polypeptides in axons [52] and the prolifera-
tion of stimulated lymphocytes, decreased tumor necro-
sis factor-α (TNF-α) receptors, induced (at 1–30 mmol/
dm3) murine macrophages to express TNF-α mRNA and 
genes associated with the LPS-induced macrophage 
activation, and induces protein tyrosine phosphorylation 
[52,53,63,64]. Paclitaxel inhibits secretory functions of 
specialized cells, catecholamine from adrenal medullar 
cells, plasma proteins from rat liver cells, and prothrom-
binase from platelets [52].
9. The side effects of paclitaxel
Common side effects include nausea and vomiting, 
loss of appetite, change in taste, thinned or brittle hair, 
pain in the joints of the arms or legs lasting two to three 
days, changes in the color of the nails, and tingling in 
the hands or toes [65]. More serious side effects such 
as unusual bruising or bleeding, change in normal bow-
el habits for more than two days, fever, chills, cough, 
sore throat, difficulty swallowing, dizziness, shortness 
of breath, severe exhaustion, skin rash, facial flushing, 
female infertility by ovarian damage, and chest pain can 
also occur. A number of these side effects are the results 
of other excipients in the applied preparation.
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10. Methods for monitoring of pacli-
taxel concentration
For monitoring paclitaxel in parenteral dosage forms, 
a validated RP-HPLC method was used [66], and is 
adequate for routine determination in pharmaceutical 
dosage form. Separation of the analyzed samples was 
done on US C18 column, where the mobile phase is a 
methanol and aqueous solution of potassium dihydro-
gen phosphate of 0.02 mol/dm3 ratio 80:20 v/v (pH of 2.5 
was adjusted with phosphoric acid). The flow rate was 1 
cm3/min1, and wavelength, 225 nm. Retention time of pa-
clitaxel was 4.978 min under these conditions. The de-
tector response was linear in the range 15–180 μg/cm3.
 There is also a sensitive, specific, and reproduc-
ible HPLC method for quantitative determination of 
paclitaxel in plasma, tissue and tumor mice. Samples 
of liver, kidney, spleen, lung, heart, and tumor tissues 
were separately homogenized in bovine serum albumin 
(BSA, 40 g/dm3. Homogenates of plasma or tissue (0.1 
cm3), containing paclitaxel and inter standard (dimethyl-
4,4’-dimethoxy-5,6,5’,6’-dimethilen dioxy biphenyl-2,2’ 
dicarboxilate), were extracted with ethyl acetate (10 
cm3). An ODS column was used for separation of com-
ponents from the biological samples. The samples were 
recorded at 227 nm. A gradient system containing ace-
tonitrile and deionized water was used for quantification 
of paclitaxel. This HPLC method has been successfully 
used for determination of paclitaxel for pharmacokinetic 
and biodistribution studies.
 Monitoring of paclitaxel concentration and verapamil 
in rats blood plasma is possible using a HPLC method 
with isocratic mode and UV detection [67]. First, the 
plasma samples were exposed to one-step liquid-liquid 
extraction by terc-buthyl methyl ether. Paclitaxel, vera-
pamil and n-buthyl p-hydroxy benzoate, as inter stan-
dard, were separated very well on an ODS column. As 
the mobile phase, this method used a mixture of am-
monium acetate buffer (50 mmol/dm3, pH 6.0) and ace-
tonitrile (54:46, v/v). Another HPLC method has been 
applied for rapid and simple determination of paclitaxel, 
without prior sample preparation, in the presence of 
polyoxyl castor oil [68].
 To lower the administered doses of paclitaxel to re-
duce its side effects, the ability to measure lower con-
centrations of paclitaxel is important. Baldery et al. have 
developed two methods, one using HPLC-UV and the 
other, LC-MS-MS [69]. In the HPLC-UV method, devel-
oped to analyze the paclitaxel in dog toxicokinetic stud-
ies, paclitaxel was extracted from human plasma by a 
simple solid phase extraction on cyano cartridges. For 
analysis, the volume of plasma between 0.5 and 1.0 cm3 
is necessary, which can sometimes be a problem for 
toxicology studies in small animals. The compound was 
eluted from the cartridges with a mixture of acetonitrile 
and triethylamine (1000:1, v/v). The eluate was evapo-
rated and the compound was dissolved in the mobile 
phase; the sample was then injected onto an Apex-Octyl 
column (150×4.6 mm). The mobile phase of acetonitrile: 
methanol : ammonium acetate (0.02 mol/dm3, pH 5) in 
a proportion of 4:1:5 (v/v/v) was run at 1 cm3/min. The 
samples were detected at 227 nm.
 The LC-MS-MS method used human plasma (0.1 
cm3). The cleanup of the samples was performed by an 
L-L extraction using diethyl ether to extract paclitaxel 
from plasma at pH 4 (by addition of ammonium acetate). 
The sample tubes were rotary mixed and centrifuged. 
The organic layer was transferred and blown to dryness. 
The compound was dissolved in a mobile phase and 
then injected onto a Hypersil C1 column (100×2.1 mm). 
The mobile phase was mixture of acetonitrile and aque-
ous formic acid (0.1%, v/v) in a proportion 1:1 (v/v).
11. Conclusion
Paclitaxel, as anticancer drug, can be isolated from Tax-
us species. It occurs as a metabolite of a special fungus. 
The microbiological route characteristically involves a 
shorter time for paclitaxel production compared with 
synthetic procedures. Its main disadvantage is a low 
yield of the bioactive substance. In medicine, paclitaxel 
is usually used for treatment of ovarian, breast, lung, 
and prostate cancer. Different types of carriers are used 
to improving its solubility and stability. Analytical meth-
ods have been developed and validated for monitoring 
the paclitaxel content in pharmaceutical formulation.
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